Persistent Pain and Its Impact on Quality of Life COVID-19 Patients That Required Critical Care

Quality of Life Clinical Trial

Official title:

Persistent Pain and Its Impact on Quality of Life at 3, 6 and 12 Months in COVID-19 Patients Who Have Required Critical Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04887220
• Other study ID #: IIBSP-COV-2020-63
• Status: Completed
• Start date: February 15, 2021
• Est. completion date: March 1, 2023

Study information

• Verified date: March 2023
• Source: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

COVID-19 infection produces thousands of hospital admissions in a very short period of time, including critical care patients. It is expected that those who survive a severe spectrum of the disease, will present some degree of health decline in the medium and long term, becoming chronic patients.

Post-intensive care syndrome (PICS) was described by the Society of Critical Care Medicine (SCCM) as a new altered or worsening of physical, cognitive, or mental condition due to critical illness and persisting after hospitalization, including pain. Also, clinical features of infection include different types of pain, and if this pain persists, it can turn into a chronic condition. Chronic pain is a currently recognized disease, but under-treated in many cases, generating a significant deterioration in the quality of life of this patient. It is vitally important to generate early care circuits to detect and treat those expected complications, such as chronic pain in these patients. The objective of this study is to estimate the level of persistent pain and its impact on health-related quality of life after admission to an intensive care unit in patients who suffered this infection.

Description:

The presence of persistent pain and impaired quality of life in COVID19 patients who have required intensive care can affect up to a total of 50% of patients.

Main objective Estimate the level of persistent pain and health-related quality of life after admission one in intensive care unit in COVID-19 patients, a new disease that has been accompanied by great health, social and economic involvement from which we do not know the long-term consequences in this patient cohort.

Secondary goals

• Assessing patient's characteristics before ICU admissión; the prevalence of painkillers use, including opioids, history of previous pain, and comorbidities. Find relationships between these characteristics and the development of chronic pain.

• Determine if some ICU treatments and patient's characteristics may contribute to persistent pain in COVID-19 survivors ( number of prone therapies, thromboembolic complications, and medication for sedate used)

• Determine the quality of life using the SF-12 test.

• Determine pain characteristics using the ID-PAIN test.

• Determine the scale of anxiety and depression using the HADs test.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: March 1, 2023
• Est. primary completion date: May 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Post ICU COVID 19 Survivor

• Adult 18 year or older, who gives its approval to participate

Exclusion Criteria:

• Refusal to participate

• Neurological or physical secuale, disabled to answer a questionnaire

Related Conditions & MeSH terms

• Chronic Pain
• Post ICU Syndrome
• Quality of Life

Locations

Country	Name	City	State
Spain	Hospital de la Santa Creu i Sant Pau	Barcelona	Catalunya

Sponsors (1)

Lead Sponsor	Collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	VAS scale value	Chronic pain in PostICU COVID19 survivors, measured by VAS scale from Brief Pain Inventory Questionnaire	1 year
Secondary	Quality of life score	Quality of life assessment by SF-12 questionnarie, of ICU survivors after 12 months of ICU discharge	1 year
Secondary	ID Pain test value	Pain characteristics of ICU COVID 19 survivors, using ID PAIN test for presence of neuropathic pain	1 year
Secondary	HAD scale value	Level of anxiety and/or depression in post ICU survivors of COVID 19 at 12 months after discharge, using HAD questionnarie	1 year